Evotec
Sergey Grechin has a diverse work experience spanning various roles and industries. Sergey is currently working as a Lead Software Developer at Evotec since 2022. Prior to that, they worked as a Freelance Software Development Consultant at Telesero Cloud from 2017 to 2022. Sergey also served as a CTO/Co-founder at auction.ru from 2015 to 2022. Sergey has experience in business development as the Business Development Director at Molotok.Ru from 2013 to 2015. Sergey also held multiple positions at Molotok.Ru, including Head of Software Development Department/Head of regional office/Project Manager from 2011 to 2012. Earlier in their career, they worked at MERA as a Project Manager, Assistant Project Manager, and Software Designer from 2006 to 2011. Sergey began their career as a Design Engineer at FGUP OKBM Afrirantova in 2003 and worked as a Research Assistant at NIRFI from 1999 to 2002.
Sergey Grechin holds a PhD in Information Technologies in Economics from NNSU (Nizhny Novgorod State University), which they obtained from 2005 to 2009. Prior to that, they completed their MPhil in Mathematics, Mechanics, and Computer Science at the same university from 1999 to 2005. In addition to their formal education, Sergey has also obtained various certifications, including a Goethe-Zertifikat B2 from Goethe-Institut e.V. in 2023, a TensorFlow Developer Certificate from TensorFlow Certificate Program in 2021, an AWS Solution Architect Associate from Amazon Web Services (AWS) in 2019, and a Certificate in Advanced English with Grade A from Cambridge Assessment International Education in 2019.
This person is not in the org chart
This person is not in any offices
Evotec
5 followers
Evotec AG is a drug discovery and development company. The Company operates through two segments. The EVT Execute segment provides standalone drug discover services on a typical fee-for-service basis or integrated drug discovery collaborations on partners' target through a range of commercial structures, including research fees, milestones and/or royalties. The EVT Innovate segment develops drug discovery programs and assets, both internally or through academic collaborations. The Company seeks to partner these into collaborations in return for upfront payments, ongoing research payments. It consists of all partnerships derived from its internally developed assets and platforms and its participations in certain companies. It includes clinical initiations and progress of clinical pipeline within partnerships; expansion of academic BRIDGE network; research and development (R&D) progress with CureX/Target X initiatives, and focuses on induced pluripotent stem cells (iPSC) platform.